Nusinersen
Empowering SMA Patients,
Accessible SMA Therapy
"What did we do?"
Strategic Milestones: Nusinersen Project Excellence
- Comprehensive Impurity Profiling
- Definitive Sameness Studies
- Strategic CDMO Partnership
Advanced Impurity Profiling & Characterization
We conducted a comprehensive comparative impurity study against the Reference Listed Drug (RLD) to ensure the highest purity standards. Our rigorous characterization included:
- Sequence Integrity: Full-Length Product (FLP), Shortmers (N-1), and Longmers (N+1).
- Modification Variants: Detailed analysis of 2'-MOE and 2'-O-EOE substitutions, including base-specific variants (mocG, mocA, moe-meU, moe-meC).
- Process-Related Species: Characterization of CNET, ADP/IDP artifacts, and comprehensive monitoring of front-eluting and post-eluting impurities.
Definitive Sameness Studies
- Mass Spectrometry (MS/MS):
- Determines the exact molecular weight of nusinersen to verify its chemical composition.
- Tandem MS (MS/MS) fragments the oligonucleotide to confirm its sequence integrity and identify any impurities or degradation products.
- Nuclear Magnetic Resonance (NMR) Spectroscopy:
- Validates the three-dimensional structure of nusinersen, ensuring correct base pairing and backbone conformation.
- Detects potential structural deviations or modifications.
- Liquid Chromatography (LC):
- Separates nusinersen from impurities, excipients, or process-related byproducts.
- Quantifies purity and monitors stability under storage conditions.
- Duplex Melting Temperature (Tm):
- Measures the thermal stability of the duplex formed between nusinersen and its complementary RNA strand.
- Reflects binding strength and hybridization efficiency, critical for its mechanism of action.
- Circular Dichroism (CD) Spectroscopy:
- Analyzes the secondary structure (e.g., A-form helix) of nusinersen.
- Ensures proper folding and conformational stability.
- Differential Scanning Calorimetry (DSC):
- Assesses thermal stability by measuring heat absorption during structural transitions (e.g., denaturation).
- Evaluates batch-to-batch consistency and formulation robustness.
- Size Exclusion Chromatography (SEC):
- Determines the oligonucleotide size distribution and detects aggregates or fragments.
- Ensures nusinersen remains monomeric and within specified size limits.
- Sedimentation Velocity Analytical Ultracentrifugation (SV-AUC):
- Provides high-resolution analysis of molecular weight, shape, and aggregation state.
- Validates homogeneity and confirms the absence of higher-order aggregates.
Strategic CMO Partnership
Collaborated with Asymchem, a premier FDA-inspected site, to ensure GMP-compliant scale-up and high-quality "Exhibition Batch" production.

